Celcuity (CELC) AI Stock Analysis

Company Guidance

Management guided that Revtopik (gedatolisib) shipments are expected to begin late Q3 2026 and an sNDA for the PIK3CA‑mutant VICTORIA‑1 cohort will be submitted in Q3 2026 with global filings to follow; WAC is $10,000 per vial ($30,000 per cycle), Celcuity estimates ~37,000 U.S. second‑line HR+/HER2‑ patients, ~10 cycles/patient and >$6 billion annual TAM at WAC with an expected gross‑to‑net of ~80% (≈20% discounts). Key clinical metrics: in the PIK3CA‑mutant cohort median PFS was 11.1 months (gedatolisib triplet) vs 5.6 months (alpelisib+fulvestrant; HR 0.50) and 11.3 months (gedatolisib doublet) vs 5.6 months (HR 0.51); discontinuation rates due to AEs were ~5.2% (triplet) and 3.8% (doublet) vs 19% for alpelisib; mean gedatolisib cycles were 9.0 (wild‑type triplet; 12% still on), 10.0 (mutant triplet; 22% still on), 9.7 (wild‑type doublet; 12% still on) and 11.3 (mutant doublet; 19% still on). Financials and operational notes: Q2 net loss $78.9M ($1.44/share), non‑GAAP loss $58.7M ($1.07/share), R&D $31.1M, SG&A $35.0M, net cash used in operations $55.4M; cash and short‑term investments $754M at 6/30/2026 (proceeds from $575M convertible offering, net $557.2M; $137M term‑loan repayment) with runway into 2029; expanded access shipments have begun, the secondary manufacturing site requires FDA clearance (review often ~2–4 months; standard 4‑month cadence), and an sNDA review would be 6 months if granted priority or 10 months standard.